Reducing the burden of atrial fibrillation cost: is integrated care the answer?
Publication date: Available online 21 May 2019Source: Canadian Journal of CardiologyAuthor(s): Celine Gallagher, Jeroen Hendriks, Melissa E. Middeldorp, Adrian D. Elliott, Dennis H. Lau, Prashanthan Sanders
Publication date: Available online 14 June 2019Source: The Lancet HaematologyAuthor(s): Matthew S Davids, Danielle M Brander, Haesook T Kim, Svitlana Tyekucheva, Jad Bsat, Alexandra Savell, Jeffrey M Hellman, Josie Bazemore, Karen Francoeur, Alvaro Alencar, Leyla Shune, Mohammad Omaira, Caron A Jacobson, Philippe Armand, Samuel Ng, Jennifer Crombie, Ann S LaCasce, Jon Arnason, Ephraim P Hochberg, Ronald W TakvorianSummaryBackgroundFludarabine, cyclophosphamide, and rituximab (FCR) can improve disease-free survival for younger (age ≤65 years) fit patients with chronic lymphocytic leukaemia with mutated IGHV. However, pat...
Conclusions: Compared with standard management, the SAFETY intervention is potentially a dominant strategy for those with chronic, non-valvular AF. However, there would be substantial value in reducing the uncertainty in these estimates from further research. Trial registration: the Australian New Zealand Clinical Trials Registry (ANZCTRN 12610000221055). PMID: 31190590 [PubMed - as supplied by publisher]
Study Objectives:To evaluate continuous positive airway pressure (CPAP) treatment in patients with moderate to severe sleep-disordered breathing (SDB) after an ischemic stroke.Methods:We identified patients included in the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) who underwent polysomnography after an ischemic stroke. We compared patients without significant SDB (apnea-hypopnea index [AHI]
ConclusionsOlder age, history of atrial fibrillation and pneumonia are associated with increased risk of influenza-associated in-hospital and 90-day mortality. Statin use may decrease 90-day mortality.
Publication date: Available online 13 June 2019Source: Canadian Journal of CardiologyAuthor(s): Ian G. Stiell, M. Sean McMurtry, Andrew McRae, Ratika Parkash, Frank Scheuermeyer, Clare L. Atzema, Allan SkanesAbstractThis commentary discusses concerns raised by Canadian emergency physicians regarding Recommendations 2 and 6 from the recent CCS 2018 Update for atrial fibrillation. These recommendations narrow the window for safe cardioversion and suggest four weeks of anticoagulation for all patients undergoing urgent cardioversion regardless of their CHADS-65 status. We discuss the implications of GRADE weak recommendations...
Conditions: Atrial Fibrillation; Atrial Fibrillation, Persistent Intervention: Drug: Ivabradine Sponsor: Yale University Recruiting
Authors: Bond DA, Alinari L, Maddocks K Abstract Mantle cell lymphoma (MCL) is a heterogeneous and uncommon non-Hodgkin lymphoma that affects predominantly older patients and often is associated with an aggressive clinical course. MCL relies upon B-cell receptor signaling through Bruton tyrosine kinase (BTK); therefore, the development of the BTK inhibitors ibrutinib and acalabrutinib represents a therapeutic breakthrough. In this review, we provide a summary of the efficacy and safety data from the landmark trials of single-agent ibrutinib and acalabrutinib that led to US Food and Drug Administration approval of t...
Conclusion: MCPIP expression was higher in age-related AF than in the other patient groups and it was associated with AF-induced fibrosis.Cardiology
In general, early experience with the first-generation cryoballoon introduced an increase in radiation exposure as compared to traditional radiofrequency ablations for atrial fibrillation (AF). However, through operator vigilance and the incorporation of various techniques and technologies, procedural radiation exposure can be managed to an exceptionally low level while maintaining the safety and efficacy of the cryoballoon procedure.